Allergan’s CEO, Brent Saunders, released a social contract in which he promised to avoid “price gouging” and will limit price increases on brand-name medicines. Saunders committed to avoid major prices hikes without any corresponding increases in costs as products near patent expiration price hikes. Additionally, price increases will be limited to single-digit percentage increases no more than once a year. To read more on this topic, click here.
Last Updated on May 12, 2020 by Aimed Alliance
